ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?
Leukemia · 2024
DOI: 10.1038/s41375-024-02225-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Leukemia, 2024. Verfasst von Olaf Penack und 17 weiteren Autor:innen. Beteiligte Einrichtung: Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany. olaf.penack@charite.de. Hauptthemen laut MEDLINE: Cyclophosphamide, Graft vs Host Disease, Antilymphocyte Serum, Hematologic Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
There is a high risk of GVHD and non-relapse mortality (NRM) after allogeneic stem cell transplantations (alloSCT) from unrelated donors. Prophylaxis with rabbit anti-thymocyte globulin (rATG) is standard in Europe but post-transplantation Cyclophosphamide (PTCy) is an emerging alternative. We analyzed outcomes of rATG ( n = 7725) vs. PTCy ( n = 1039) prophylaxis in adult patients with hematologic malignancies undergoing peripheral blood alloSCT from 10/10 antigen-matched unrelated donors (MUD) between January 2018 and June 2021 in the EBMT database. The provided P -values and hazard ratios (HR) are derived from multivariate analysis. Two years after alloSCT, NRM in the PTCy group was 12.1% vs. 16.4% in the rATG group; p = 0.016; HR 0.72. Relapse was less frequent after PTCy vs. rATG (22.8% vs. 26.6%; p = 0.046; HR 0.87). Overall survival after PTCy was higher (73.1% vs. 65.9%; p = 0.001, HR 0.82). Progression free survival was better after PTCy vs. rATG (64.9% vs. 57.2%; p < 0.001, HR 0.83). The incidence of chronic GVHD was lower after PTCy (28.4% vs. rATG 31.4%; p = 0.012; HR 0.77), whereas the incidence and severity of acute GVHD were not significantly different. GVHD-free relapse-free survival was significantly higher in the PTCy arm compared to the rATG arm (2 y incidence: 51% vs. 45%; HR: 0.86 [95% CI 0.75–0.99], p = 0.035). In the absence of evidence from randomized controlled trials, our findings support a preference for the use of PTCy in adult recipients of peripheral blood alloSCTs from MUD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical Clinic, Department for Haematology, Oncology and Tumorimmunology, Charité Universitätsmedizin Berlin, Berlin, Germany. olaf.penack@charite.de.
- EBMT Transplant Complications Working Party, Paris, France. olaf.penack@charite.de.
- EBMT Transplant Complications Working Party, Paris, France.
- EBMT Paris study office; Department of Haematology, Saint Antoine Hospital; INSERM UMR-S 938, Sorbonne University, Paris, France.
- University Hospital Eppendorf, Hamburg, Germany.
- University of Muenster, Muenster, Germany.
ORCID-Profile: Olaf Penack, Nicolaus Kröger, Alexander Kulagin, Stephan Mielke, Robert Zeiser, Hélène Schoemans, Christian Koenecke
Zitieren
APA
Penack, O., Abouqateb, M., Peczynski, C., Boreland, W., Kröger, N., Stelljes, M., Gedde-Dahl, T., Blau, I. W., Schroeder, T., Salmenniemi, U., Kulagin, A., Peffault de Latour, R., Mielke, S., Zeiser, R., Moiseev, I., Schoemans, H., Koenecke, C., & Peric, Z. (2024). ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?. Leukemia. https://doi.org/10.1038/s41375-024-02225-7
Vancouver
Penack O, Abouqateb M, Peczynski C, Boreland W, Kröger N, Stelljes M, et al. ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?. Leukemia. 2024. doi:10.1038/s41375-024-02225-7
BibTeX
@article{Penack2024,
author = {Penack, Olaf and Abouqateb, Mouad and Peczynski, Christophe and Boreland, William and Kröger, Nicolaus and Stelljes, Matthias and Gedde-Dahl, Tobias and Blau, Igor Wolfgang and Schroeder, Thomas and Salmenniemi, Urpu and Kulagin, Alexander and Peffault de Latour, Régis and Mielke, Stephan and Zeiser, Robert and Moiseev, Ivan and Schoemans, Hélène and Koenecke, Christian and Peric, Zinaida},
title = {ATG or post-transplant cyclophosphamide to prevent GVHD in matched unrelated stem cell transplantation?},
journal = {Leukemia},
year = {2024},
doi = {10.1038/s41375-024-02225-7}
}
EUVIMED